Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07337265 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Royal Jelly Supplementation in Unexplained Male Infertility

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Jul 1, 2026 → Dec 1, 2026
See other at-risk trials from Medipol University

Record History

  1. Recruitment opened Primary completion pushed from Jul 1, 2026 to Dec 1, 2026 · Completion pushed from Aug 1, 2026 to Dec 1, 2026 · Study sites: 0 to 1v2 Show 3 more changesShow less
    • Primary completion pushed from Jul 1, 2026 to Dec 1, 2026
    • Completion pushed from Aug 1, 2026 to Dec 1, 2026
    • Study sites: 0 to 1
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This randomized, double-blind, placebo-controlled clinical trial investigates the effects of oral Royal Jelly supplementation on sperm DNA fragmentation and pregnancy rates in couples with unexplained infertility. While routine semen analysis appears normal (normozoospermia) in these patients, underlying Sperm DNA Fragmentation (SDF) and oxidative stress are believed to contribute to reproductive failure. Participants will be randomized to receive either 750 mg of lyophilized Royal Jelly or a placebo daily for a period of 3 months (90 days). The study aims to evaluate whether the antioxidant properties of Royal Jelly can improve sperm chromatin integrity, reduce oxidative stress markers, and increase spontaneous pregnancy rates compared to the control group
Trial Details
NCT Number NCT07337265
Lead Sponsor Medipol University
Conditions Unexplained Infertility, Male Infertility, Sperm DNA Fragmentation
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov